Thursday, November 16, 12:30pm - 2:00pm (EST)
Your search did not return any results.
The Unitaid-funded BENEFIT Kids project addresses critical research gaps to improve care for children affected by multidrug-resistant TB (MDR-TB). The program aims to reduce paediatric morbidity and mortality through better access to improved prevention and treatment strategies. BENEFIT Kids includes clinical trials incorporating efficacy, safety, pharmacokinetics, acceptability, and costing, with community involvement being central. The session aims to highlight key project findings impacting policy and practice. Raj Taneja, Vice President, Pharmaceutical Product Development at TB Alliance will provide an overview of ChilPref, a program about how children’s taste preferences informed the development of moxifloxacin and linezolid pediatric formulations.
Please see the online program for more information.
TB Alliance at the Union Conference